The short version
15 companies supply this market — deep enough that no single failure threatens the supply.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Neurontin
gabapentin · GABAPENTIN 250 mg/5mL · Solution · Oral · Viatris Specialty LLC
NDC 58151-0290-35 · 1 BOTTLE in 1 CARTON / 470 mL in 1 BOTTLE · NDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 00071-2012-47) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$1.03per unit
middle half $1.03–$1.03 · 2 plans · Apr 1, 2026
Est. net of rebatesⓘ
$0.6155–$0.7694
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
0%of plans cover it
tier 1 · prior auth 0% · step therapy 0% · qty limit 100%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Medicaid spend (2026 YTD · Q1)ⓘ
$23,472
88 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for gabapentin (other) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $1,578.20 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA021129
- TE code
- AA
- Approval date
- Mar 2, 2000
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of gabapentin (Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | GABAPENTIN 250 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Advagen Pharma Ltd | GABAPENTIN 250 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Ajenat Pharmaceuticals LLC | GABAPENTIN 250 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| American Health Packaging | GABAPENTIN 250 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Amneal Pharmaceuticals LLC | GABAPENTIN 250 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Atlantic Biologicals Corp. | GABAPENTIN 250 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| BioComp Pharma, Inc. | GABAPENTIN 250 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Bryant Ranch Prepack | GABAPENTIN 250 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Camber Pharmaceuticals, Inc. | GABAPENTIN 250 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Jvet Pharmaceuticals Llc | GABAPENTIN 250 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Kesin Pharma Corporation | GABAPENTIN 250 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Parke-Davis Div of Pfizer Inc | GABAPENTIN 250 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Remedyrepack Inc. | GABAPENTIN 250 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Viatris Specialty LLC | GABAPENTIN 250 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Kesin Pharma Corporation | GABAPENTIN 50 mg/mL | Jul 15, 2026 | Aug 31, 2026 |
| PAI Holdings, LLC dba PAI Pharma | GABAPENTIN 250 mg/5mL | Jul 15, 2026 | Aug 31, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Neurontin — NDC 58151-0290-35," retrieved September 3, 2026, https://drugdashboards.com/drug/58151029035.
Free to cite with attribution — see how the data is put together.